Hormonal contraceptive use in HIV-infected women using antiretroviral therapy: a systematic review

References

• UNAIDS/WHOThe Gap Report. Children and Pregnant Women Living with HIV201420 Available from: http://www.unaids.org/sites/default/files/media_asset/09_ChildrenandpregnantwomenlivingwithHIV.pdfAccessed December 7, 2014
   Google Scholar
• UNAIDS/WHOAIDS Epidemic Update2007 Available from: http://data.unaids.org/pub/EpiReport/2006/2006_EpiUpdate_en.pdfAccessed January 2, 2007
   Google Scholar
• TepperNKCurtisKMJamiesonDJMarchbanksPAUpdate to CDC’s U.lSMMWR Morb Mortal Wkly Rep20126124449452 Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6124a4.htmAccessed November 15, 201422717514
   PubMedGoogle Scholar
• DelvauxTNostlingerCReproductive choice for women and men living with HIV: contraception, abortion and fertilityReprod Health Matters20071529 Suppl466617531748
   PubMed Web of Science ®Google Scholar
• LeticeeNViardJPYamgnaneAKarmochkineMBenachiAContraceptive failure of etonogestrel implant in patients treated with anti-retrovirals including efavirenzContraception201285442542722036046
   PubMed Web of Science ®Google Scholar
• LakhiNGovindAImplanon failure in patients on antiretroviral medication: the importance of disclosureJ Fam Plann Reprod Health Care2010363181182
   PubMed Web of Science ®Google Scholar
• MatilukoAASoundararjanLHogstonPEarly contraceptive failure of implanon in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenzJ Fam Plann Reprod Health Care200733427727817925115
   PubMed Web of Science ®Google Scholar
• McCartyEJKeaneHQuinnKQuahSImplanon(R) failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnanciesInt J STD AIDS201122741341421729965
   PubMed Web of Science ®Google Scholar
• MassadLSEvansCTWilsonTEContraceptive use among US women with HIVJ Womens Health (Larchmt)200716565766617627401
   PubMed Web of Science ®Google Scholar
• RiveraRYacobsonIGrimesDThe mechanism of action of hormonal contraceptives and intrauterine contraceptive devicesAm J Obstet Gynecol19991815 pt 11263126910561657
   PubMed Web of Science ®Google Scholar
• FryeCAAn overview of oral contraceptives: mechanism of action and clinical useNeurology2006666 Suppl 3S29S3616567739
   PubMed Web of Science ®Google Scholar
• FleischmanDSNavarreteCDFesslerDMOral contraceptives suppress ovarian hormone productionPsychol Sci2010215750752 author reply 75320483856
   PubMed Web of Science ®Google Scholar
• LoboRAStanczykFZNew knowledge in the physiology of hormonal contraceptivesAm J Obstet Gynecol19941705 pt 2149915078178898
   PubMed Web of Science ®Google Scholar
• CroxattoHBMechanisms that explain the contraceptive action of progestin implants for womenContraception2002651212711861052
   PubMed Web of Science ®Google Scholar
• BronsonRAOral contraception: mechanism of actionClin Obstet Gynecol19812438698777026108
   PubMedGoogle Scholar
• MeyerUAOverview of enzymes of drug metabolismJ Pharmacokinet Biopharm19962454494599131484
   PubMedGoogle Scholar
• WilkinsonGRCytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humansJ Pharmacokinet Biopharm19962454754909131486
   PubMedGoogle Scholar
• WangBSanchezRIFranklinRBEvansDCHuskeySEThe involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiolDrug Metab Dispos200432111209121215304426
   PubMed Web of Science ®Google Scholar
• StanczykFZAll progestins are not created equalSteroids20036810–1387989014667980
   PubMed Web of Science ®Google Scholar
• DickinsonBDAltmanRDNielsenNHSterlingMLCouncil on scientific affairs AMA. Drug interactions between oral contraceptives and antibioticsObstet Gynecol2001985 pt 185386011704183
   PubMed Web of Science ®Google Scholar
• ReddyDSClinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptivesExpert Rev Clin Pharmacol20103218319220369030
   PubMedGoogle Scholar
• RobinsonJAJamshidiRBurkeAEContraception for the HIV-positive woman: a review of interactions between hormonal contraception and antiretroviral therapyInfect Dis Obstet Gynecol2012201289016022927715
   PubMedGoogle Scholar
• AIDSInfoGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents2014 Available from: http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0Accessed November 29, 2014
   Google Scholar
• FlexnerCHIV-protease inhibitorsN Engl J Med199833818128112929562584
   PubMed Web of Science ®Google Scholar
• SmithPFDiCenzoRMorseGDClinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitorsClin Pharmacokinet2001401289390511735608
   PubMed Web of Science ®Google Scholar
• PilieroPJPharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitorsJ Acquir Immune Defic Syndr200437Suppl 1S2S1215319664
   PubMed Web of Science ®Google Scholar
• KearneyBPMathiasALack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptivesPharmacotherapy200929892492919637945
   PubMed Web of Science ®Google Scholar
• LandoltNKPhanuphakNUbolyamSSignificant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive womenJ Acquir Immune Defic Syndr2014662e50e5224608892
   PubMed Web of Science ®Google Scholar
• MildvanDYarrishRMarshakAPharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected womenJ Acquir Immune Defic Syndr200229547147711981363
   PubMed Web of Science ®Google Scholar
• StuartGSMosesACorbettACombined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in MalawiJ Acquir Immune Defic Syndr2011582e40e4321921726
   PubMed Web of Science ®Google Scholar
• WattsDHParkJGCohnSESafety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093Contraception2008772849018226670
   PubMed Web of Science ®Google Scholar
• CohnSEParkJGWattsDHACTG A5093 Protocol TeamDepo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactionsClin Pharmacol Ther200781222222717192768
   PubMed Web of Science ®Google Scholar
• SevinskyHEleyTPerssonAThe effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative womenAntivir Ther201116214915621447863
   PubMed Web of Science ®Google Scholar
• CartenMLKiserJJKwaraAMawhinneySCu-UvinSPharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and EfavirenzInfect Dis Obstet Gynecol2012201213719222536010
   PubMedGoogle Scholar
• VieiraCSBahamondesMVde SouzaRMEffect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive womenJ Acquir Immune Defic Syndr201466437838524798768
   PubMed Web of Science ®Google Scholar
• NandaKDelany-MoretlweSDubéKNevirapine-based antiretroviral therapy does not reduce oral contraceptive effectivenessAIDS201327Suppl 1S17S2524088680
   PubMed Web of Science ®Google Scholar
• Scholler-GyureMKakudaTNRaoofADe SmedtGHoetelmansRMClinical pharmacokinetics and pharmacodynamics of etravirineClin Pharmacokinet200948956157419725591
   PubMed Web of Science ®Google Scholar
• CrauwelsHMvan HeeswijkRPVandevoordeABuelensAStevensMHoetelmansRMThe effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteersJ Clin Pharmacol201454213314024203510
   PubMed Web of Science ®Google Scholar
• DuBoisBNAtrioJStanczykFZCheralaGIncreased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapyContraception2015911717525245190
   PubMed Web of Science ®Google Scholar
• OuelletDHsuAQianJEffect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteersBr J Clin Pharmacol19984621111169723818
   PubMed Web of Science ®Google Scholar
• FrohlichMBurhenneJMartin-FacklamMOral contraception does not alter single dose saquinavir pharmacokinetics in womenBr J Clin Pharmacol200457324425214998420
   PubMed Web of Science ®Google Scholar
• VoglerMAPattersonKKamemotoLContraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188J Acquir Immune Defic Syndr201055447348220842042
   PubMed Web of Science ®Google Scholar
• ZhangJChungEYonesCThe effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy womenAntivir Ther201116215716421447864
   PubMed Web of Science ®Google Scholar
• SekarVJLefebvreEGuzmanSSPharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy womenAntivir Ther200813456356918672535
   PubMed Web of Science ®Google Scholar
• AndersonMSHanleyWDMoreauAREffect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy womenBr J Clin Pharmacol201171461662021395656
   PubMed Web of Science ®Google Scholar
• AbelSRussellDWhitlockLARidgwayCEMuirheadGJEffect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteersBr J Clin Pharmacol200865Suppl 1192618333862
   PubMed Web of Science ®Google Scholar
• KasserraCLiJMarchBO’MaraEEffect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy womenClin Ther201133101503151422015327
   PubMed Web of Science ®Google Scholar
• BensonCAHuaLAndersenJWZOSTAVAX is generally safe and immunogenic in HIV-Infected adults with CD4 counts > 200 cells/microliter virologically suppressed on antiretroviral therapy: results of a phase 2, randomized, double-blind, placebo-controlled trial (A5247)Paper presented at: Conference on Retroviruses and Opportunistic InfectionsMarch 5–8, 2012Seattle, WA
   Google Scholar
• ViiV Healthcare Tivicay (Dolutegravir) Package LabelResearch Triangle Park, NCViiV Healthcare2013Accessed October 14, 2014
   Google Scholar
• AbbVie IKaletra (Lopinavir/Ritonavir) Package LabelChicago, ILAbbVie Inc2013Accessed October 11, 2014
   Google Scholar
• FotherbyKAkpoviroroJAbdel-RahmanHAPharmacokinetics of ethynyloestradiol in women for different populationsContraception19812354874967285572
   PubMed Web of Science ®Google Scholar
• GoldzieherJWSelected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implicationsAm J Obstet Gynecol19901631 pt 23183222196804
   PubMed Web of Science ®Google Scholar
• GoldzieherJWStanczykFZOral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestinsContraception20087814918555811
   PubMed Web of Science ®Google Scholar
• WomackJRichmanSTienPCGreyMWilliamsAHormonal contraception and HIV-positive women: metabolic concerns and management strategiesJ Midwifery Womens Health200853436237518586190
   PubMed Web of Science ®Google Scholar
• WellsGHSheaBO’ConnellDThe Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses2014 Available from: http://www.ohri.ca/programsclinical_epidemiology/oxfordaspAccessed October 15, 2014
   Google Scholar
• ClarkRATheallKPTrends and correlates of hormonal contraception use among HIV-infected womenJ Acquir Immune Defic Syndr200436498698815220707
   PubMed Web of Science ®Google Scholar
• PerrySHSwamyPPreidisGAMwanyumbaAMotsaNSareroHNImplementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnanciesAIDS201428579179324401645
   PubMed Web of Science ®Google Scholar
• DanelCMohRAnzianATolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West AfricaJ Acquir Immune Defic Syndr2006421293516763490
   PubMed Web of Science ®Google Scholar
• KreitchmannRInnocenteAPPreusslerGMSafety and efficacy of contraceptive implants for HIV-infected women in Porto Alegre, BrazilInt J Gynaecol Obstet20121171818222249127
   PubMed Web of Science ®Google Scholar
• HeikinheimoOLehtovirtaPSuniJPaavonenJThe levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women – effects on bleeding patterns, ovarian function and genital shedding of HIVHum Reprod200621112857286116880227
   PubMed Web of Science ®Google Scholar
• HeikinheimoOLehtovirtaPAhoIRistolaMPaavonenJThe levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up studyAm J Obstet Gynecol20112042126e1e421035781
   PubMed Web of Science ®Google Scholar
• HubacherDLikuJKiarieJEffect of concurrent use of anti-retroviral therapy and levonorgestrel sub-dermal implant for contraception on CD4 counts: a prospective cohort study in KenyaJ Int AIDS Soc2013161844823458102
   PubMed Web of Science ®Google Scholar
• HeffronRMugoNNgureKPartners in Prevention HSVHIV Transmission Study TeamHormonal contraceptive use and risk of HIV-1 disease progressionAIDS201327226126723079806
   PubMed Web of Science ®Google Scholar
• StringerEAntonsenEHormonal contraception and HIV disease progressionClin Infect Dis200847794595118715161
   PubMed Web of Science ®Google Scholar
• Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and AdolescentsConsiderations for Antiretroviral Use in Special Patient Populations: HIV-Infected Women2013 Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/glchunk/glchunk_23.pdfAccessed November 15, 2014
   Google Scholar
• WHOHormonal Contraceptive Methods for Women at High Risk of HIV and Living with HIV: 2014 Guidance Statement2014 Available from: http://apps.who.int/iris/bitstream/10665/128537/1/WHO_RHR_14.24_eng.pdfAccessed November 15, 2014
   Google Scholar
• Supplement: Safety and Toxicity of Individual Antiretroviral Agents in PregnancyPublic Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States2007 Available from: http://www.aidsinfo.nih.gov/contentfiles/PerinatalGLSafetyTox_Sup.pdfAccessed December 7, 2014
   Google Scholar
• WomackJAScotchMLeungSNUse of structured and unstructured data to identify contraceptive use in women veteransPerspect Health Inf Manag2013101e
   Google Scholar
• Guttmacher InstituteFact Sheet: Contraceptive use in the United StatesNew York, NYGuttmacher Institute2014Accessed October 21, 2014
   Google Scholar
• Growth in World Contraceptive Use Stalling215 Million Women’s Needs Still Unmet [webpage on the Internet]Washington, DCEarth Policy Institute2012 [cited March 27, 2012]. Available from: http://www.earth-policy.org/data_highlights/2012/highlights26Accessed October 27, 2014
   Google Scholar
• Bristol-Myers SquibbReyataz (Atazanavir) Package LabelNew York, NYBristol-Myers Squibb2014Accessed October 12, 2014
   Google Scholar
• Boehringer-Ingelheim Pharmaceuticals IAptivus (Tipranavir) Package LabelIngelheim am Rhein, GermanyBoehringer-Ingelheim2014Accessed October 27, 2014
   Google Scholar
• GlaxoSmithKlineLexiva (Fosamprenavir) Package LabelBrentford, UKGlaxoSmithKline2009Accessed October 24, 2014
   Google Scholar
• PfizerSelzentry (Maraviroc) Package LabelNew York, NYPfizer2009Accessed October 11, 2014
   Google Scholar
• Gilead Sciences IStribild Package LabelFoster City, CAGilead Sciences2012Accessed October 27, 2014
   Google Scholar
• LandoltNKPhanuphakNUbolyamSEfavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptivesJ Acquir Immune Defic Syndr201362553453923187949
   PubMed Web of Science ®Google Scholar